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A B S T R A C T
Phosphaturic mesenchymal tumours are a heterogeneous set of bone and soft tissue neoplasms that can cause a
number of paraneoplastic syndromes such as tumour induced osteomalacia. The term phosphaturic comes from
the common ﬁnding that these tumours secrete high levels of ﬁbroblast growth factor 23 which causes renal
phosphate wasting leading to hypophosphatemia. Phosphaturic mesenchymal tumours are rare and diagnosis is
diﬃcult. A very active 68 year old male presented with bone pain and muscle weakness. He was hypopho-
sphataemic and total alkaline phosphatase was markedly elevated. The patient was placed on vitamin D sup-
plementation but his condition progressed. In the ﬁfth year of presentation the patient required the use of a
wheelchair and described “explosive” bone pain on physical contact. Serum 1,25 dihydroxyvitamin D was low
and serum ﬁbroblast growth factor 23 was signiﬁcantly elevated, raising suspicion of a phosphaturic me-
senchymal tumour. A lesion was detected in his left femoral head and the patient underwent a total hip re-
placement. The patient displayed a rapid improvement to his condition and during a three year follow up period
he returned to an active lifestyle. As molecular testing may help provide a robust diagnosis and is particularly
useful in rare diseases we took a next generation sequencing approach to identify a diﬀerential expression of
small RNAs in the resected tumour. Small RNAs are non-coding RNA molecules that play a key role in regulation
of gene expression and can be used as speciﬁc biomarkers. We found an upregulation of miR-197. We also found
a downregulation of miR-20b, miR-144 and miR-335 which is a small RNA proﬁle typical of osteosarcoma. MiR-
21, the most frequently upregulated microRNA in cancer, was downregulated. We conclude that the speciﬁc
small RNA proﬁle is typical of osteosarcoma except for the downregulation of oncogenic miR-21. Transcriptional
plasticity of miR-197, which is computationally predicted to target ﬁbroblast growth factor 23 messenger RNA,
may be upregulated in a cellular eﬀort to correct the ectopic expression of the protein.
1. Introduction
Fibroblast growth factor 23 (FGF23) interacts with the ﬁbroblast
growth factor receptor 1-klotho (FGFR1-KL) complex in renal tubules.
The FGF23-FGFR1-KL interaction negatively regulates phosphate re-
uptake (Berndt and Kumar, 2007). Abnormally high circulating blood
concentrations of FGF23 can be caused by ectopic secretion from
phosphaturic mesenchymal tumours (PMTs) resulting in phosphate
wasting and hypophosphatemia. Hypophosphatemia leads to decreased
mineralisation of the bones and can contribute to tumour induced
osteomalacia (TIO). FGF23 also blocks the expression of cytochrome
P450 family 27 subfamily B member 1 (CYP27B1) which prevents the
conversion of 25 hydroxyvitamin D (25(OH)D) to 1,25 dihydrox-
yvitamin D (1,25(OH)2D). Low 1,25(OH)2D reduces osteoid miner-
alisation (Chong et al., 2011). PMTs are typically low grade and require
a step-wise approach to investigation utilising imaging and sometimes
selective venous sampling for measurement of FGF23 to locate the le-
sion (Chong et al., 2011).
There have been few molecular studies of PMT that delineate un-
derstanding of their development and ectopic expression of FGF23
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causing paraneoplastic syndromes. The existing studies observe ﬁ-
bronectin 1 (FN1)-FGFR1 fusion genes in 60% of PMTs causing TIO (Lee
et al., 2015). Unlike prototypical leukemia inducing FGFR1 fusions,
which are ligand independent, the FN1-FGFR1 chimeric protein pre-
serves its binding domains for FGF23 (Lee et al., 2015). Hypoxia in-
ducible factor 1 alpha (HIF1A) has been observed to induce ectopic
expression of FGF23 (Zhang et al., 2016). Hypoxia is a known driver of
tumourigenesis by reducing the activity of oxygen dependent Tet me-
thylcytosine dioxygenases (TETs) which are required for DNA de-
methylation of tumour suppressor genes (Thienpont et al., 2016).
We report a patient who presented with clinical and biochemical
signs of TIO and in whom radiological appearances were consistent
with renal osteodystrophy despite good renal function. Further in-
vestigation identiﬁed the presence of a PMT. Surgical resection of the
tumour relieved the symptoms and corrected the biochemical ab-
normalities.
2. Case report
A 68 year old man had been in excellent health working as a farmer
and performing manual labour until he presented with back pain and
lower limb weakness. At presentation, magnetic resonance imaging
(MRI) of the spine revealed a diﬀuse punctate reduction in signal on
both T1 and T2 weighted sequences interspersed with areas of normal
marrow fat signal. Conventional radiographs demonstrated poorly de-
ﬁned coarse trabeculae in the femoral necks that were characteristic of
osteomalacia (Fig. 1A). There were periosteal reactions in the proximal
tibia and patchy sclerosis in the proximal humerus and distal tibia
(Fig. 1B). Serum biochemistry analysis using the Architect 8000 (Ab-
bott, Maidenhead, UK) revealed the patient was hypophosphataemic
with phosphate at 0.4 mmol/L (reference range 0.8–1.5 mmol/L) and
total alkaline phosphatase was elevated at 400 U/L (reference range
38–126 U/L) (Fig. 2A and B). The patient was prescribed with 500 mg
of calcium and 400 IU of vitamin D3 per day but showed no improve-
ment. He remained hypophosphataemic for the next ﬁve years.
In the ﬁfth year since presentation the patient described “explosive”
bone pain on physical contact. He now required the use of a wheelchair
because of severe muscle weakness. Serum phosphate was now
0.52 mmol/L (reference range 0.8–1.5 mmol/L) and total alkaline
phosphatase was now 213 U/L (reference range 38–126 U/L). Serum
1,25(OH)2D (Radioimmunoassay, IDS, Boldon Colliery, UK) was
31 pmol/L (reference range 43–143 pmol/L) and C-Terminal FGF23
(Immutopics, Athens, USA) was 438 RU/mL (reference
range < 100 RU/mL) (Fig. 2C and D). Liquid chromatography tandem
mass spectrometry (LC-MS/MS) after protein precipitation detected 25
hydroxyvitamin D (25(OH)D) at 76 nmol/L (reference range
50–120 nmol/L). Adjusted calcium (Cobas® 6000, Roche, Burgess Hill,
UK) was 2.4 mmol/L (reference range 2.1–2.6 mmol/L), creatinine
(Cobas® 6000, Roche, Burgess Hill, UK) was 88 μmol/L (reference range
55–125 μmol/L) and intact parathyroid hormone (Cobas® 6000, Roche,
Burgess Hill, UK) was 5.2 pmol/L (reference range 1.6–6.9 pmol/L).
These ﬁfth year investigations are summarised in Table 1 and were
suggestive of a paraneoplastic syndrome. The patient was placed on
vitamin D3 supplementation at 20,000 IU per week for three months
followed by 1000 IU per day for nine months. The patient was referred
for radiography, bone densitometry, co-registered positron emission
tomography/computerised tomography (PET/CT) and octreotide scin-
tigraphy.
Dual-energy X-ray absorptiometry (DXA) revealed bone mineral
density (BMD) in the lumbar spine was 1.498 g/cm2 with a T-score of
3.7. BMD in the left femoral neck was 1.274 g/cm2 with a T-score of
1.6. A radionuclide bone scintigram demonstrated multifocal radio-
tracer uptake in keeping with extensive insuﬃciency fractures invol-
ving the humeri, ribs, left glenoid, sacrum, left proximal femur and
tibiae (Fig. 1C). CT of the chest, abdomen and pelvis revealed extensive
sclerosis of the axial skeleton. Corresponding to an area of focal uptake
in the left femoral head the CT demonstrated a well-deﬁned lesion of
the same attenuation as adjacent marrow and demarcated by a thin
sclerotic rim (Fig. 1D). Pelvic and spinal sclerosis had increased since
original presentation (Fig. 1E). PET/CT with 18Fludeoxyglucose showed
focal tracer accumulation in the left femoral head corresponding to a
lucent lesion surrounded by sclerosis (Fig. 1F). There was new diﬀuse
sclerosis evident throughout the pelvis and lumbar spine. The combi-
nation of osteosclerosis and osteomalacia suggested a radiological di-
agnosis of renal osteodystrophy but this was not supported by the
normal renal function.
A decalciﬁed one centimetre trephine bone biopsy of the lesion
detected in the left femoral head showed trabecular thickening with
increased woven and lamellar bone (Fig. 1G). The trabeculae had un-
dulating surfaces suggesting previous remodelling activity. Osteoid,
osteoblasts and osteoclasts were not conspicuous (Fig. 1G). Many tra-
beculae had a variable and thin zone of faintly basophilic staining at the
surface possibly representing mineralised osteoid, though this ob-
servation is limited due to the decalciﬁcation method. The marrow
contained an abnormal cellular inﬁltrate of variable density. Some
areas were loosely cellular but others were more crowded and con-
tained numerous overlapping hyperchromatic nuclei. Some nuclei
showed streaming, other nuclei were palisaded. Nuclei were oval or
grain shaped and had ﬁnely granular chromatin (Fig. 1G). Mitoses were
rare. The cytoplasm was sparse and ill-deﬁned. Cells were strongly
immunoreactive for vimentin, CD56 and CD99. Cells did not stain for
cytokeratins, smooth muscle actin, desmin, S100 protein, CD31, CD34,
or CD117. There was a rich background capillary network (CD31,
CD34) with interlinking branching vessels. Stromal calciﬁcation was
present in small quantities. There was no necrosis. These observations
were compatible with those described in PMT (Goldblum et al., 2013).
The conﬁrmed tumour was resected by total hip replacement. The
specimen was received immediately from theatre allowing fresh sam-
ples to be taken for molecular studies. After ﬁxing in 10% formal saline,
decalciﬁcation and routine processing to paraﬃn wax blocks, histo-
pathological examination showed features similar to those in the
biopsy. The neoplasm was composed of spindle shaped cells and had an
inﬁltrative growth pattern. The lesion periphery appeared generally
looser than the centre which was more compact and densely cellular. In
places the tumour invested small arteries like a sleeve and appeared to
inﬁltrate their media. Sections of formalin ﬁxed paraﬃn embedded
tumour specimen were incubated with an anti-FGF23 monoclonal an-
tibody (AdipoGen, Liestal, Switzerland) for 24 h at ambient tempera-
ture after paraﬃn removal, rehydration and antigen retrieval using
boiling EDTA (1 mM, pH 8). Endogenous peroxidase activity was in-
hibited by treatment with 3% hydrogen peroxide for 10 min at ambient
temperature. The sections were then incubated with a 1:1000 horse-
radish peroxidase labelled secondary antibody (Abcam, Cambridge,
UK) for 1 h at ambient temperature. Diaminobenzidine solution was
used for visualisation followed by nuclear counterstaining with hae-
matoxylin. Speciﬁcity of the FGF23 staining was determined by staining
a serial section of the specimen using the same protocol with an isotope
control antibody at the same concentration (Fig. 1H). The PMT section
containing the anti-FGF23 monoclonal antibody showed positive
staining for FGF23 (Fig. 1I).
During a three year follow up period since surgery the patient re-
ported a rapid improvement of his condition and serum biochemistry
normalised (Fig. 2A–D). He no longer required a wheelchair, was
working again on his farm and performing heavy manual labour.
To the best of our knowledge a PMT associated with osteosclerosis
has not previously been described. To gain molecular insight we took a
next generation sequencing approach to investigate the small RNA
population in the tumour. Small RNAs are non-coding RNA molecules
that are key regulators of gene expression by negatively regulating
target messenger RNAs (Green et al., 2016). Small RNAs such as mi-
croRNAs (miRNAs) can potentially be used to classify poorly diﬀer-
entiated tumours, distinguish between diﬀerent subtypes of tumour
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originating from the same tissue and as biomarkers in various bioﬂuids
(Rosenfeld et al., 2008; Yanaihara et al., 2006; Schetter et al., 2008;
Blondal et al., 2013). Small RNA library construction and next gen-
eration sequencing is biased. If there is low complementarity between
the adapter and small RNA the two molecules are less likely to be an-
nealed and ampliﬁed. Small RNAs that are less likely to anneal to
adapters are less likely to be sequenced. We previously developed high
deﬁnition (HD) adapters which contain four degenerate assigned nu-
cleotides on each of the ligating ends of HiSeq 2500 adapters (Sorefan
et al., 2012; Xu et al., 2015). HD adapters increase annealing eﬃciency,
reduce ligation bias and recover more small RNA sequences for analysis
(Xu et al., 2015). We used HD adapters to identify diﬀerential expres-
sion of miRNAs in the PMT when compared to controls.
3. Materials and methods
3.1. Ethics for non-clinical procedures
This study was approved by the Faculty of Medicine and Health
Sciences Research Ethics Committee. Clinical material was obtained
from the Norwich Biorepository which collected bone tissue from the
Norfolk and Norwich University Hospital. The patient and control co-
hort provided written informed consent to donate tissue for this study.
3.2. Control samples
Control samples were obtained from the bone tissue of trauma pa-
tients following a neck of femur fracture (ages 68–86, 3 women and 2
men). Exclusion criteria for control samples were the known presence
of malignancy, metabolic or inﬂammatory disease.
3.3. Next generation sequencing
Bone and tumour tissue was homogenised under liquid nitrogen
conditions using the BioPulverisor (BioSpec, Bartlesville, USA). Total
RNA was extracted using the miRCURY RNA isolation kit (Exiqon,
Vedbaek, Denmark) according to manufacturer's instructions. RNA
concentration and integrity was measured on the NanoDrop 8000
Spectrophotometer (Thermo Fisher Scientiﬁc, Paisley, UK) and visually
assessed by agarose gel electrophoresis with ethidium bromide staining.
RNA was stored at−80 °C. All libraries were constructed using 1 μg of
RNA which was ligated to 3′ and 5′ HD adapters (Xu et al., 2015). Li-
gated RNA products were reverse transcribed to cDNA and ampliﬁed by
PCR. The cDNA products expected to contain 19–33 base pair inserts
were selected and puriﬁed by 8% polyacrylamide gel electrophoresis
and ethanol precipitation. We performed next generation sequencing on
the HiSeq 2500 Ultra-High Throughput Sequencing System (Illumina,
San Diego, USA) at the Earlham Institute, Norwich Research Park.
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Fig. 1. The clinical course of a patient who presented with bone pain and muscle weakness. (A) Anteroposterior radiographs of the left femoral head and neck, demonstrating the typical
but often subtle features of conventional osteomalacia with coarse ill-deﬁned secondary trabeculae (arrow). (B) Anteroposterior radiograph of the right tibia demonstrating medial and
lateral periosteal reactions along the proximal metaphysis (arrows). (C) Radionuclide bone scintigram demonstrating “H” shaped radiotracer uptake in the sacrum (arrow) with smaller
foci of radiotracer uptake in the proximal tibiae (arrowheads). Proximal humeri, left glenoid, left lesser trochanter, right distal tibia and multiple ribs display focal, oft linear tracer
accumulation in keeping with insuﬃciency fractures. (D) Anterior and posterior late phase images from on octreotide radionuclide examination demonstrating radiotracer uptake (arrow)
in the left femoral head. (E) A coronal reformatted CT of the pelvis demonstrates a lesion in the left femoral head of the same attenuation as the surrounding medulla but demarcated by a
thin sclerotic margin (arrow). There is diﬀuse medullary sclerosis throughout the lumbar spine (arrowhead). (F) Coronal fused 18Fluorodeoxyglucose demonstrating increased tracer
uptake in the lesion. (G) Photomicrograph at 20×magniﬁcation of the lesion biopsy stained with haematoxylin and eosin. There is irregularly thickened trabecular bone with intervening
densely cellular tumour. (H) Photomicrograph at 40× magniﬁcation of anti-FGF23 negative control. (I) Photomicrograph at 40× magniﬁcation of anti-FGF23 positive staining.
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3.4. Bioinformatics analysis
Raw fastq ﬁles were converted to fasta format. Reads containing
unassigned nucleotides (Ns) were excluded. The 3′ HD adapter was
trimmed using perfect sequence similarity to the ﬁrst 8 nucleotides (nt)
of the 3′ HiSeq 2500 adapter (TGGAATTC). The HD signatures from
both the 5′ and 3′ ends were also trimmed (Stocks et al., 2012). Reads
with low sequence complexity, i.e. with an overrepresentation of one
nucleotide for> 60% of the sequence length, were excluded. As part of
the quality check the size class distributions for redundant and non-
redundant reads were plotted side by side with the complexity dis-
tributions (Mohorianu et al., 2011). Reads were mapped full length
with no gaps or mismatches to the human genome (v38) and corre-
sponding annotations using PatMaN (Prufer et al., 2008). The latest set
of human miRNAs was downloaded from miRBase v21 (Kozomara and
Griﬃths-Jones, 2014). Small RNA expression levels were normalised
using a scaling approach, reads per total, to a ﬁxed total of 10 million
reads (Table 2) (Mortazavi et al., 2008). As with all human studies there
was variability in control samples (when compared to inbred genetic
models such as mice and fruit ﬂies where variability is minimal) so
diﬀerentially expressed reads between the tumour and control samples
were identiﬁed using both an expression interval approach and pair-
wise comparison using oﬀset fold change with an empirically de-
termined oﬀset of 20 (Mohorianu et al., 2011, 2013; Beckers et al.,
2017). Comparison of the replicates was conducted using scatter plots,
size-split boxplot of the replicate-to-replicate diﬀerential expression,
intersection and Jaccard similarity analyses (Mohorianu et al., 2011).
The analysis was conducted using custom-made Perl (5.24.0.1) and R
(3.2.2) scripts.
4. Results
Matching against the human genome (v38) and corresponding an-
notations showed a size class distribution of the redundant reads re-
sembling a bimodal distribution (Fig. 3A) and non-redundant reads
resembling an even distribution (Fig. 3B). A bimodal distribution of
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Fig. 2. Serum biochemistry performed on a patient who presented to our clinic with bone pain and muscle weakness. In the ﬁfth year we detected 1,25(OH)2D deﬁciency and C-Terminal
FGF23 elevation which initiated the search for a PMT. A PMT was discovered and resected and the patient was followed up for three years. (A) Serum phosphate is consistently deﬁcient
until normalised by tumour resection. (B) Serum total alkaline phosphatase is signiﬁcantly elevated on ﬁrst presentation. Concentrations gradually declined and returned to normal two
years post-resection. (C) Serum 1,25(OH)2D is investigated in the ﬁfth year and reported to be deﬁcient. The eﬀects of vitamin D supplementation are clearly visible post-resection when
CYP27B1 is no longer inhibited by C-Terminal FGF23 produced by the tumour. (D) Serum C-Terminal FGF23 is investigated in the ﬁfth year and reported to be signiﬁcantly elevated.
Tumour resection normalises C-Terminal FGF23. C-Terminal FGF23 now remains at the upper limit of the reference range. In all ﬁgures the dotted red lines represent the upper and lower
limit of the reference range. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Serum biochemistry performed on a patient who presented ﬁve years earlier with bone
pain, muscle weakness, low serum phosphate and elevated total alkaline phosphatase.
Now in the ﬁfth year he presented with “explosive” bone pain on physical contact and
required the use of a wheelchair because of severe muscle weakness. Serum biochemis-
tries were repeated with further investigations performed for 25(OH)D, 1,25(OH)2D,
FGF23, adjusted calcium, creatinine and intact parathyroid hormone. Phosphate, total
alkaline phosphatase, 1,25(OH)2D and C-Terminal FGF23 were abnormal (in red) leading
to the suspicion of a paraneoplastic syndrome.
Analyte Diagnostic method Value Reference range Units
Phosphate Architect 8000 (Abbott) 0.52 0.8–1.5 mmol/L
Total alkaline phosphatase Architect 8000 (Abbott) 213 38–126 U/L
1,25(OH)2D RIA (IDS) 31 43–143 pmol/L
C-Terminal FGF23 ELISA (Immutopics) 438 <100 RU/mL
25(OH)D LC-MS/MS 76 50–120 nmol/L
Adjusted calcium Cobas® 6000 (Roche) 2.4 2.1–2.6 mmol/L
Creatinine Cobas® 6000 (Roche) 88 55–125 µmol/L
Intact parathyroid hormone Cobas® 6000 (Roche) 5.2 1.6–6.9 pmol/L
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redundant reads and even distribution of non-redundant reads is in line
with previous human studies which use HD adapters for small RNA
library construction (Sorefan et al., 2012; Green et al., 2017). The
distribution of complexities shows a low complexity at 22 and 32 nt,
corresponding to miRNAs and tRNA fragments. Low complexities are
characterised by a small number of highly abundant sequences
(Fig. 3C). Among the diﬀerentially expressed miRNAs, miR-197 was
found to be upregulated compared to controls and miR-20b, miR-21,
miR-144, and miR-335 were downregulated (Fig. 3D–H).
5. Discussion
We describe a patient who presented with bone pain and muscle
weakness. Although his radiology was consistent with renal
osteodystrophy, this diagnosis was dismissed due to his normal renal
function. As his health deteriorated, later investigation revealed an
FGF23-producing PMT in the left femoral head. The majority of PMT
cases are associated with TIO. This case diﬀers from conventional de-
scriptions of TIO because of the diﬀuse sclerosis that aﬀected the axial
and parts of the appendicular skeleton. In other atypical cases where
osteomalacia and osteosclerosis co-present it has been considered that
vitamin D supplementation to treat osteomalacia may play a role in
causing osteosclerosis, though our biochemical analysis shows a sup-
pression of the active metabolite 1,25(OH)2D (Edelson et al., 1993).
The radiographic appearance of the trabeculae in the femoral necks is
typical of osteomalacia when they are poorly deﬁned and coarse. Later
in the progression of the disease the trabeculae became more con-
spicuous as the sclerosis progressed. Acquired diﬀuse osteosclerosis can
Table 2
Overview of the sequencing output for control (CTRL) and PMT libraries. We show total number of reads obtained per sample, total number of accepted reads which did not contain
unassigned nucleotides, total number of non-redundant reads and overall sample complexities (C) which is deﬁned as the ratio of non-redundant to redundant reads. We also show the
percentage of genome matching reads assigned to miRNAs and tRNA fragments.
Total reads Accepted reads Adapter reads Non-redundant reads C Genome match (%) miRNA match (%) tRNA match (%)
PMT 20,4513,66 15,231,963 14,959,567 535,957 0.035 73 44 38
CTRL 26,735,842 26,711,859 17,171,584 911,323 0.057 73 28 9
CTRL 14,090,445 14,077,678 10,211,115 741,722 0.079 71 13 14
CTRL 28,948,651 28,922,976 25,836,859 800,979 0.034 80 34 31
CTRL 26,936,015 26,911,371 24,367,300 811,143 0.034 84 15 39
CTRL 35,001,366 34,969,913 33,113,846 653,789 0.020 87 5 74
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Fig. 3. Bioinformatics and sequencing analysis of next generation sequencing data. PMT size class distribution for (A) redundant reads (B) non-redundant reads (C) complexities. The size
class distribution of the redundant reads is a bimodal distribution with peaks at 22 nt (miRNAs) and 32 nt (tRNA fragments). We also observe a low complexity at 22 and 32 nt (miRNAs
and tRNA fragments respectively) which indicates the presence of a small number of highly abundant small RNA reads. Abundance of diﬀerentially expressed miRNAs between the
tumour (in red) compared to normal samples (in black). (D) miR-20b-5p (E) miR-21-5p (F) miR-144-5p (G) miR-197-3p (H) miR-335-5p. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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be seen in a number of conditions. In this clinical context myeloﬁbrosis
or mastocytosis might be the most important diﬀerential diagnosis with
potentially similar patterns of sclerosis. Bone dysplasias such as pyc-
nodysostosis and osteopetrosis could be excluded by the progressive
nature of the condition. The slow indolent course of the disease did not
ﬁt with lymphoma, sclerotic metastases or diﬀuse sclerosing myeloma.
The combination of osteosclerosis and osteomalacia pointed to a me-
tabolic aetiology. While renal osteodystrophy might be the most
common cause for these appearances the renal function did not support
this diagnosis. In this case a less common defect in phosphate meta-
bolism needed to be considered.
Physical examination and serum biochemistry initiated the search
for a PMT. PET/CT examination identiﬁed a lesion in the left femoral
head which was conﬁrmed by biopsy as a PMT. Resection of the tumour
resulted in prompt resolution of the biochemical abnormalities and
rapid improvement of the patient's condition. To investigate the mo-
lecular biology of a PMT associated with osteosclerosis we performed
next generation sequencing to identify diﬀerential expression of
miRNAs. We found a downregulation of miR-20b, miR-144 and miR-
335 (Fig. 3D–H). This miRNA signature is similar to previous ob-
servations in osteosarcoma (Wang et al., 2013, 2015; Liu et al., 2016).
MiR-335 has been shown to negatively regulate translation of rho as-
sociated coiled-coil containing protein kinase 1 (ROCK1) (Wang et al.,
2013). The role of ROCK1 is to promote cytoskeletal changes associated
with cancer cell migration and metastasis. MiR-20b has been shown to
negatively regulate translation of HIF1A and inhibit the proliferation
and migration of osteosarcoma cells (Liu et al., 2016). Upregulation of
HIF1A has previously been linked to sarcoma metastasis (El-Naggar
et al., 2015). We also found a downregulation of miR-21 which is one of
the most frequently upregulated miRNAs in cancer. MiR-21 acts by
suppressing the translation of phosphatases which normally inhibit the
activity of protein kinase B (PKB) and mitogen-activated protein kinases
(MAPK) signalling (Musilova and Mraz, 2015). We speculate that miR-
21 downregulation in this case may underlie the apparently benign
phenotype despite the osteosarcoma miRNA proﬁle.
We used TargetScan v7.1 to identify targets of miR-197 which we
observe to be upregulated. FGF23 transcript was identiﬁed as a pre-
dicted target for canonical seed region matching and silencing by miR-
197. The cellular transcriptome is a dynamic set of transcripts which is
able to respond to endogenous and exogenous signals (Green et al.,
2016). Our ﬁnding of an upregulated miRNA to target a hypoxia in-
duced transcript, FGF23, is supportive of a previous prediction that
increased transcriptional plasticity and negative regulation of ectopi-
cally expressed genes may act as an innate cellular defence mechanism
in order to maintain genomic homeostasis (Green et al., 2016).
PMT was ﬁrst used in 1987 as an umbrella term to comprise the
diverse mesenchymal lesions that lead to phosphate wasting. The ma-
jority of PMTs (> 80%) are mixed connective tissue variants which
consist of sheets of primitive stromal cells with small nuclei interposed
with a proliferating vascular component containing giant cells and
multiple foci of immature cartilage, osteoid and bone (Shane et al.,
1997). It will be important to perform further research into miRNA
proﬁles in other PMTs to observe if diﬀerences exist in such tumours or
if there is consistency in the proﬁle that could be used as a diagnostic/
prognostic tool. Our ﬁndings should be compared with future PMT
cases that result in non-sclerotic type lesions. The patient described in
this report was investigated for ﬁve years before an underlying tumour
was considered, located and resected, demonstrating the diﬃculty that
can exist in making the diagnosis early in the disease. In future it may
be possible to examine circulating cells or molecules to look at a proﬁle
of markers to help conﬁrm the molecular diagnosis.
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